CONSHOHOCKEN, PA--(Marketwire - Feb 7, 2012) - NuPathe Inc. (NASDAQ: [ PATH ]), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that [ Jane Hollingsworth ], chief executive officer, will present company overviews at two upcoming investor conferences.

On Tuesday, February 14, 2012, NuPathe will present at the [ 14th Annual BIO CEO & Investor Conference ] at 3:00 p.m. EST. The conference is being held at The Waldorf Astoria Hotel in New York, NY.

On Wednesday, February 15, 2012, NuPathe will present at the Leerink Swann 2012 Global Healthcare Conference at 4:00 p.m. EST. The conference is also being held at The Waldorf Astoria Hotel in New York, NY.

Live audio webcasts of the presentations will be available via the "Investor Relations" page of the NuPathe website, [ www.nupathe.com ]. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. Replays of the webcasts will also be archived on NuPathe's website for 90 days following the presentation.

About NuPathe
[ NuPathe ] Inc. ([ www.nupathe.com ]) is an emerging biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, [ NP101 ], is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates in preclinical development: [ NP201 ] for the continuous symptomatic treatment of Parkinson's disease, which the company plans to partner, and [ NP202 ] for the long-term treatment of schizophrenia and bipolar disorder.